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ABSTRACT
Objectives: This study aims to asses the effects of estradiol vs. raloxifene on the levels of osteoprotegerin and soluble 
Receptor Activator of Nuclear Factor kB Ligand (sRANKL) in Human Umbilical Vein Endothelial Cells (HUVEC) culture in 
standard and calcifying medium.
Material and methods: Human Umbilical Vein Endothelial Cells were isolated from human umbilical vein by standard 
method. The supernatant concentrations of osteoprotegerin (OPG) and sRANKL (ELISA) were determined after incubation 
with glicerophosphate, estradiol , raloxifene, glicerophoshate and estradiol, glicerophosphate and raloxifene in comparison 
with control group at four designated time points (0, 1, 2 and 4 days of incubation).
Results: Incubation of estradiol with HUVEC colony lowered the OPG level significantly after day 2 and 4. Meantime, the 
level of sRANKL was stable. Raloxifene added to standard growth medium also significantly lowered OPG concentration 
after day 4 only, with no impact on sRANKL concentration. When added to calcifying medium, both estradiol and raloxifene 
significantly changed OPG level during the experiment. In all treated groups OPG levels were lower than in groups exposed 
to calcifying medium only. Neither estradiol, nor raloxifene changed sRANKL levels during the experiment.
Conclusions: Estradiol and raloxifene affect OPG secretion from endothelial cells in vitro which may suggest their modify-
ing role in pathogenesis of vascular calcification in postmenopausal women.
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INTRODUCTION
It has been proved that during the calcification of vessels 
occur similar processes to those in bone tissue biomineraliza-
tion. In depositions located in both lamina interna and media 
of the vessel wall, matrix vesicles were identified [1]. Samples 
from the walls of calcified vessels as well as in vitro studies 
revealed the expression of macromolecular matrix proteins 
involved in the regulation of biomineralization, i.e.: bone 
morphogenetic protein -2 (BMP-2), osteopontin, matrix gla 
protein (MGP), osteonectin, collagen, osteocalcin , and the 
osteoprotegerin/receptor activator factor NF-κB/ receptor ac-
tivator factor NF-κB ligand system (OPG/RANK/RANKL) [2–4].
Over the last few years intensive studies have been 
carried out to assess the OPG/RANK/RANKL system con-
tribution to vascular calcification (VC) process. Osteopro-
tegerin appears to represent the molecular link between 
bone resorption and vascular calcification, and may help 
to understand the high prevalence of atherosclerosis and 
osteoporosis in postmenopausal women. Serum OPG is 
potentially an independent predictor of early vascular ad-
verse changes in osteoporotic postmenopausal women [5]. 
Helas showed that unopposed RANKL activity in osteopro-
tegerin-deficient mice resulted in osteoporosis and vascu-
lar calcification. RANKL inhibition by denosumab reduced 
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vascular calcification in prednisolon-induced osteoporosis 
in mice, which is further evidence for the link between the 
bone and vascular system [6]. 
Estrogen therapy for postmenopausal women reduces 
vascular calcification [7–9]. It has been shown that post-
menopausal women with a higher serum estradiol (E2) level 
had a reduced coronary artery calcium score independent 
of age and other coronary risk factors. Possibly, estradiol 
lowers the calcified-plaque burden of coronary arteries in 
postmenopausal women [10]. This is due to the indirect 
effect on calcification risk factors as well as direct genomic 
and extragenomic effect on macrophages, endothelial cells 
and vascular smooth muscle cells (VSMCs). Estradiol has 
been found to modulate the secretion of matrix proteins 
(osteopontin, BSP, MGP, RANKL/OPG), attenuates prolifera-
tion and differentiation of VSMCs as well as the activity of 
calcifying cells [7, 11, 12].
Raloxifene is a non-steroid, selective estrogen receptor 
modulator (SERM) demonstrating, depending on target 
tissue, either agonistic or antagonistic effects. Raloxifene 
therapy involves beneficial impact on cardiovascular risk 
factors: increases concentration of HDL-cholesterol, and de-
creases level of LDL-cholesterol, fibrynogen, homocysteine, 
and lower intensity of inflammatory processes [7, 13–17]. 
Raloxifene, used in postmenopausal osteoporosis therapy, 
affects the synthesis and release of intercellular matrix pro-
teins, proliferation and differentiation of VSMCs [12] and 
has a protective effect on vascular endothelium by, among 
others, increased expression of eNOS [18–19].
Animals subjected to ovariectomy demonstrated sub-
stantial increase of calcium deposit accumulation in the 
vessel wall as well as an increase of the OPG/RANKL ratio, 
primarily resulting from a decrease of RANKL concentration 
(as opposed to the bone system) [20]. Clinical trials have 
established that raloxifene therapy significantly lowers the 
level of RANKL and temporally decreases the level of OPG 
(which normal level is restored after a year of therapy). 
Main store of OPG is the bones and cardiovascular system. 
It is still unclear whether the influence of raloxifene on the 
concentration of OPG and RANKL in serum is mainly due to 
its osteoprotective effect, or to the processes occurring in 
the vessel wall [21].
The increase of osteoporosis parallel to the development 
of calcification in postmenopausal women proves that the 
role of female sex hormones is vital for the regulation of 
deposition and resorption processes in bone tissue. Despite 
long-term research, the influence of hormone replacement 
therapy on the cardiovascular system is still subject to de-
bate. The mechanisms involving the reducing effect of SERM 
(i.e. raloxifene) on cardiovascular events rate in postmeno-
pausal need to be deeply examined.
The aim of the study
Direct effects of raloxifene on endothelial OPG/ 
/RANK/RANKL system have not yet been studied. Therefore, 
we decided to test that 17β-estradiol and raloxifene would 
influence endothelial in vitro secretion of OPG/RANKL in 
calcifying milieu which may support this way for modifying 
vascular calcification. 
MATERIAL AND METHODS
Chemicals
17β-estradiol, raloxifene hydrochloride, β-glyce-
rophosphate disodium salt hydrate, dimethyl sulfoxide 
(DMSO) were purchased from Sigma Chemical (St. Louis, MO). 
Cell culture — Human Umbilical  
Vein Endothelial Cells (HUVEC)
Human umbilical vein obtained from healthy adult 
woman was cannulated and filled with 0.1% collagenase 
solution (Sigma-Aldrich, USA), then incubated for 10 mi- 
nutes at 37°C. After incubation, the vein was perfused with 
HBSS solution without Ca++ and Mg++ (Sigma-Aldrich, 
USA). Cells were collected from the perfusate by centrifuga-
tion (200g, 4°C), and suspended in Medium199 containing 
15% bovine calf serum, 100 U/mL penicillin G, 100µg/mL 
streptomycin, 0.25µg/mL amphotericine B, 100µg/mL low 
molecular weight heparin and 200µg/mL Endothelial Cell 
Growth Supplement, buffered with 25mM HEPES (all rea-
gents Sigma-Aldrich, USA). Cells were cultured in fibronectin 
precoated flasks (Nalge Nunc International, USA). Primary 
culture was passaged after washing and trypsinization. Cells 
from third subcultures were used for the experiments.
All cell cultures were maintained in a humidified 5% 
CO2 atmosphere at 37
oC. Human Umbilical Vein Endothe-
lial Cells (HUVEC) were divided into groups and incubated 
with glicerophosphate (group 2), raloxifene (3), estradiol (4), 
glicerophosphate and estradiol (5), glicerophosphate and 
raloxifene (6), and control group (1), which received solvent 
(10-9 m/L DMSO) used for estradiol and raloxifene. That day, 
when we administered substances described above was 
called day 0. Concentrations of raloxifene and estradiol were 
established on the basis of literature for efficacy at physi-
ological levels [22]. Medium was changed at day 1, 2 and 
4. Supernatants from examined and control HUVEC were 
collected on days 1, 2, and 4 for determination of protein 
concentrations. All samples were frozen at –80oC till the day 
of measurements.
Laboratory procedures
Human OPG and soluble RANKL (sRANKL) levels were 
measured in HUVEC supernatants using sandwich-type 
enzyme-linked immunosorbent assay (ELISA) kits according 
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to the manufacturers’ instructions. The human OPG ELISA kit 
was purchased from RayBio, and human sRANKL kits were 
purchased from Tecomedical Group. Note of, the ELISA assay 
for human sRANKL from Tecomedical Group detects only 
uncomplexed soluble RANKL.
Statistical analysis
The median, 1 and 3 quartiles values were calculated for 
each group of data. The results were evaluated by using the 
Mann-Whitney rank-sum test and post-hoc Conover test. 
Correlation were calculated by the Spearman’s method. 
Statistical significance was defined as p less than 0.05. All 
analyses were carried out by using Statistica software (ver-
sion 10.0 PL, StatSoft, Tulsa, OK, USA).
RESULTS
Control group
Concentration of OPG and sRANKL was determined at 
each of the four designated time points (Tab. 1, Tab. 2). There 
was no significant difference in concentration of OPG at each 
of the designated time points but there was a tendency to 
decrease the OPG level during the experiment (Fig. 1). The 
level of sRANKL increased statistically at day 4 comparing 
with day 0 and 1 (p0vs4 = 0.001, p1vs4 = 0.003) (Fig. 2). There 
was no significant correlation between OPG and sRANKL 
concentration (day 1: R = –0.5, p = 0.24, day 2: R = –0.09, 
p = 0.84, day 4: R = –0.07, p = 0.81).
The effect of glicerophosphate  
on OPG and sRANKL secretion
OPG levels showed a significant and time-dependent 
linear decrease in supernatants from HUVEC exposure to 
medium containing excess phosphate (p0vs4 = 0.03 and 
p1vs4 = 0.01). Comparing to the control group OPG concen-
tration was statistically lower in glicerophosphate group 
on day 1,2 and 4 (p = 0.037, p = 0.004 and p = 0.001 re-
spectively) (Fig. 1). There were no significant difference in 
sRANKL concentration in cultures containing glicerophos-
phate (Fig. 2).
Table 1. Concentration of OPG (pg/mL) in the supernatants of control HUVEC and in cells incubated with analyzed substances
OPG (pg/mL) Day 0 Day 1 Day 2 Day 4
Control group 32.88(Q1-30.2, Q3-7.01)
36.42
(Q1-33.3, Q3-39.4)
31.13
(Q1-27.5, Q3-35.4)
28.09
(Q1-23.9, Q3-32.7)
Glicerophosphate 25.76(Q1-25.6, Q3-34.6)
30.74
(Q1-21.5, Q3-32.2)
25.7
(Q1-21.2, Q3-27.4)
20.96
(Q1-15.6, Q3-23.9)
Estradiol 27.85(Q1-27.1, Q3-33.2)
29.85
(Q1-26.6, Q3-35.61)
26.02
(Q1-25.4, Q3-27.4)
23,12
(Q1-16.2, Q3-25.5)
Raloxifene 30.01(Q1-26.34, Q3-38.35)
30.04
(Q1-26.09, Q3-34.82)
28.07
(Q1-24.81, Q3-28.91)
18.74
(Q1-15.2, Q3-21.23)
Glicero+ Estradiol 31.92(Q1-30.3, Q3-39.9)
26.67
(Q1-16.1, Q3-32.4)
18.35
(Q1-14.5, Q3-19.9)
13.17
(Q1-9.2, Q3-15.0)
Glicero+Raloxifene 30.87(Q1-28.14, Q3-33.43)
26.05
(Q1-17.28, Q3-29.81)
13.86
(Q1-12.20, Q3-16.80)
9.04
(Q1-7.55, Q3-10.87)
Abbreviations: Glicero — glicerophosphate
Table 2. Concentration of sRANKL (pmol/L) in the supernatants of control HUVEC and in cells incubated with analyzed substances
sRANKL (pmol/L) Day 0 Day 1 Day 2 Day 4
Control group 0.12(Q1-0.04, Q3-0.16)
0.14
(Q1-0.04, Q3-0.18)
0.17
(Q1-0.09, Q3-0.19)
0.22
(Q1-0.17, Q3-0.26)
Glicerophosphate 0.15(Q1-0.10, Q3-0.32)
0.23
(Q1-0.06, Q3-0.68)
0.18
(Q1-0.09, Q3-0.22)
0.22
(Q1-0.18, Q3-0.44)
Estradiol 0.17(Q1-0.11, Q3-0.49)
0.09
(Q1-0.07, Q3-0.25)
0.18
(Q1-0.11, Q3-0.19)
0.2
(Q1-0.16, Q3-0.24)
Raloxifene 0.11(Q1-0.07, Q3-0.29)
0.11
(Q1-0.07, Q3-0.27)
0.14
(Q1-0.09, Q3-0.17)
0.19
(Q1-0.14, Q3-0.30)
Glicero+ Estradiol 0.18(Q1-0.12, Q3-0.23)
0.27
(Q1-0.10, Q3-0.57)
0.18
(Q1-0.14, Q3-0.19)
0.19
(Q1-0.17, Q3-0.22)
Glicero+Raloxifene 0.11(Q1-0.09, Q3-0.24)
0.2
(Q1-0.06, Q3-0.39)
0.13
(Q1-0.09, Q3-0.17)
0.2
(Q1-0.17, Q3-0.22)
Abbreviations: Glicero — glicerophosphate
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The effect of estradiol and raloxifene treatment 
on resting endothelial OPG  
and sRANKL secretion
Incubation of estradiol with HUVEC colony lowered the 
OPG concentration significantly on day 4 when compared 
with day 0 and 1 (p = 0.0009 and p = 0.0004, respectively). 
Comparing to control group OPG secretion was significantly 
lower on day 4 (p = 0,006) (Fig. 1). The level of sRANKL 
after a fall at day 1, showed a tendency to increase on day 
2 and 4. Comparing to control group estradiol did not affect 
sRANKL levels (Fig. 2).
Raloxifene added to standard growth medium signifi-
cantly lowered OPG level on day 4 only (p = 0,008) (Fig. 1). 
sRANKL levels decreased on day 1, and then showed a ten-
dency to increase in groups exposed to medium contain-
ing raloxifene. Comparing to the control group raloxifene 
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Figure 1. Concentration of osteoprotegerin (OPG) in the supernatants of HUVEC
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significantly lowered OPG concentration on day 4 (p = 0.0009) 
with no impact on sRANKL level (Fig. 1 and 2).
The effect of estradiol and raloxifene treatment 
on OPG and sRANKL expression in HUVEC 
exposed to calcifying medium
When added to calcifying medium, both estradiol and 
raloxifene significantly changed OPG level during the ex-
periment. In all treated groups OPG concentration were 
lower than in groups exposed to calcifying medium only, 
reaching a statistically significant difference on day 2 and 
4 (p < 0.05) (Fig. 1). When comparing with groups contain-
ing glicerophosphate, raloxifene significantly lowered the 
OPG level on day 4 only. Meantime, estradiol lowered OPG 
concentration on day 2 and 4.
Neither estradiol nor raloxifene changed sRANKL levels 
during the experiment (Fig. 2).
DISCUSSION
Evidence from the last years have drawn attention to 
the relationship between vascular calcification (VC) and 
bone health. The mechanisms involved in VC are still not 
fully understood but recent studies have shown that 
RANK/RANKL/OPG plays an important role in regulating 
those processes. The exact functions of these molecules in 
relation to VC are still unclear. OPG is produced by VSMCs 
and may be upregulated by inflammatory modulators or 
downregulated by anti-inflammatory factors [23]. OPG is 
also produced by ECs and may serve as an EC survival signal 
to oppose the pro-apoptotic actions of TRAIL. 
Elevated OPG levels may exert an anti-calcific effect 
within the vasculature, protect against arterial damage and 
VC, or reflect a general state of EC dysfunction. However, 
the protective role of OPG found in the animal model has 
not been observed in humans. In contrast, in humans many 
authors suggest a positive association between serum OPG 
and atherosclerosis, arterial calcification, or CV disease [24]. 
High serum concentrations of OPG were correlated to the 
severity of peripheral arterial disease [25] and heart failure 
[26], unstable angina [27], acute myocardial infarction and 
risk of death [28]. Bjerre [29] reports that increased levels of 
OPG are not directly involved with the extent of myocardial 
injury. The author also reports that high levels of OPG would 
be a biomarker for cardiovascular complications.
RANKL may be considered as an important factor in the 
pathogenesis of VC, but a definitive relationship between 
RANKL and bone-vascular axis in CKD patients remains un-
clear. Only few studies reported that RANKL is related to 
cardiovascular events. RANKL secreted by ECs is able to 
activate RANK receptor and promote an osteogenic differ-
entiation of VSMCs [7]. Cardiovascular events and mortality 
are significantly higher in these patients with low serum 
sRANKL levels. Lieb et al. [30] reported that serum RANKL 
concentrations is not related to carotid arteries calcification 
(CAC), the incidents of CVD or mortality. Higher levels of total 
RANKL were inversely correlated with CAC and triglycerides 
in postmenopausal woman [31]. Samelson concluded, that 
RANKL inhibition with denosumab treatment had no effect 
on progression of aortic calcification or incidence of adverse 
cardiovascular events in postmenopausal women with os-
teoporosis and high cardiovascular risk [32].
There is a significant association between BMD loss 
and vascular calcifications in the aorta in postmenopausal 
women. Low estradiol levels could be involved in the deve- 
lopment of both coronary calcification and BMD loss. There 
are several pathophysiological mechanisms that could ex-
plain the role that estrogens play in vascular calcification 
inhibition. Firstly, estradiol prevents atherosclerotic plaque 
development [33]. Administration of E2 decreases VSMC 
proliferation in animal and human models, through ac-
tivation of nitric oxide synthase and through decreased 
mitogen-induced VSMC proliferation. Secondly, VSMC and 
endothelial cells express RANK, RANKL and OPG, and there-
fore can respond to RANKL stimulation. RANKL induces 
VC through an increase in bone morphogenetic protein 
and a decrease in matrix Gla protein, an inhibitor of VC. 
Estradiol is able to attenuate RANKL-induced VC [7, 33]. 
Therefore, through differential actions in the expression of 
key proteins, E2 preserves the original contractile VSMCs 
features, decreasing transdifferentiation towards a calcify-
ing phenotype.
To the best of our knowledge this is the first study pre-
senting the influence of calcification-promoting culture con-
ditions and female sex hormones on the OPG and sRANKL 
release in vitro. Under standard conditions, stable levels of 
osteoprotegerin and gradually increasing concentration of 
soluble RANKL were observed throughout the experiment. 
Substantial changes have also been shown in the release 
of the proteins under unfavorable, calcification-promoting 
culture conditions, as well as in cultures subjected to hor-
mone stimulation. Under hyperphosphatemic conditions, 
OPG concentrations dropped steadily with each day of the 
experiment, while sRANKL values remained stable. The ad-
dition of estradiol or raloxifene had no effect on OPG and 
sRANKL concentrations. 
In the control group osteoprotegerin concentration 
was stable while the values of sRANKL exhibited significant 
linear increase. Changes in concentrations of the analyzed 
substances may be related to physical shortcomings of the 
culture. Lekesiz, using the same HUVEC culture model (but 
observed only over several hours) hasfound the increase 
in OPG release and the drop in sRANKL secretion by en-
dothelial cells [34]. In our study, differences in OPG release 
may result from the time of measurement: most probably, 
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certain unfavorable physical and mechanical factors trigger 
the secretion of Weibel-Palade bodies content, which in turn 
causes temporary rise in OPG concentration followed by its 
drop before the protein is produced de novo.
It is still not completely clear whether concentration of 
OPG in the blood can serve as a marker of the intensity of 
the atherosclerotic process, a mediator of its progression, or 
an indicator of natural defense against calcification of the 
vascular wall. In our experiment calcification-promoting 
conditions caused lower OPG concentrations with stable 
levels of sRANKL. Since we did not use an hourly observa-
tion protocol, it is difficult to predict the early changes in 
the concentration of analyzed substances. Decreasing OPG 
concentrations may be explained either by excessive OPG 
release in the early hours of the experiment and its further 
exhaustion (which would be in line with Lekesiz’s findings), 
or by the neutralization of OPG by means of its binding to 
sRANKL.
The in vitro studies have shown that estradiol or ra-
loxifene maintain VSMCs’ OPG production when cultured 
under elevated levels of calcium phosphates [22]. We have 
confirmed that under calcification-promoting conditions, 
endothelial cells change the sRANKL and OPG release. In 
normophosphatemic conditions, both estradiol and ralo- 
xifene caused a decrease in concentrations of OPG , which 
suggested either reduced production or increased con-
sumption of that protein. 
Unlike VSMCs, both drugs used in the experiment did 
not prevent a hyperphosphatemia-induced drop in OPG 
concentration. In normal, as well as when cultured under 
elevated levels of calcium phosphates conditions, we found 
lower OPG concentration in EC colony treated with E2 or 
raloxifene This may suggest that endothelial cells respond 
differently than VSMCs especially under unfavorable liv-
ing conditions. However, in order to deeply determine the 
profile of OPG/sRANKL secretion by endothelial cells we 
would need to determine this response in different period 
of time that is shorter and longer than the culture originally 
designed by our team. Another thing that would also be 
worth considering is the assessment of other factors that 
seem to be important for the initiation of the vascular calcifi-
cation process as well as mRNA expression of those proteins.
CONCLUSIONS
In conclusion, we found that estriadiol and raloxifene 
decreased OPG secretion and did not maintain endothelial 
cell OPG production when cultured under elevated levels 
of calcium phosphates. Serum OPG concentration, seen in 
many cardiovascular pathology, seems to be dependent on 
VSMCs rather than EC release.
Despite osteoprotegerin is being a potent inhibitor of 
bone loss, higher serum levels of this cytokine are marker 
of calcification-related vascular diseases. A deeper knowl-
edge of the mechanisms involved in the association be-
tween OPG serum levels, bone integrity and cardiovascular 
disease can provide important data for future therapeutic 
interventions.
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